TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) reported record monthly sales as the medical-technology company expands distribution of its temperature-control products for medications.
TempraMed reported preliminary sales of approximately US$522,000 in July 2026, marking the highest monthly total in its history. August sales reached approximately US$403,000, representing the company’s second-highest monthly result.
Sales for the eight months ended August 31 totaled approximately US$2.07 million. That figure is roughly 15% above the approximately US$1.8 million TempraMed generated during all of 2025.
“Our year-to-date sales have already surpassed total sales for all of last year,” CEO Ron Nagar said.
The figures are preliminary, unaudited estimates and remain subject to change as TempraMed completes its financial closing procedures. The update uses the term “sales” and does not provide corresponding information about gross margins, operating expenses, cash flow or profitability.
TempraMed develops reusable thermal-insulation products designed to protect temperature-sensitive medications from exposure to excessive heat or cold. Its product portfolio includes VIVI Cap, VIVI Cap Smart, VIVI Epi and VIVI Med. The devices operate continuously without batteries or an external power source.
The company has historically sold products directly to consumers but is expanding through pharmacies, distributors, healthcare systems and institutional customers. Management attributed recent growth partly to increased awareness of temperature exposure risks and broader use of injectable medications, including insulin and GLP-1 therapies.
Orders from larger commercial customers can make monthly results more volatile. TempraMed cautioned that the timing of orders from institutional, pharmacy and distribution partners may vary and that its recent monthly performance may not be sustained.
The company expects its third-quarter sales to be significantly higher than in the corresponding 2025 period. However, that projection remains forward-looking and will need to be evaluated against TempraMed’s completed quarterly financial statements.
TempraMed is also pursuing expansion across North America, Israel, Europe, Latin America and the Middle East. Converting that distribution activity into recurring sales while managing manufacturing, regulatory and financing requirements will be important as the company scales.
Upcoming Catalysts
TempraMed expects to publish its completed third-quarter financial statements in November. Those results should clarify how much of the preliminary sales total is reflected in recognized revenue and whether increased sales produced stronger margins or cash flow.
Investors may also watch for additional pharmacy, healthcare-system and distribution agreements, repeat institutional orders and further geographic expansion. Because the recent update did not include profitability figures, the company’s expense levels and working-capital requirements will remain important considerations.
Sources
- TempraMed Reports Record July Sales and Strong August Performance
- TempraMed corporate website
- SEDAR+ regulatory filings
Editorial Disclosure
This article is based entirely on publicly available company announcements and regulatory disclosures. Next Gen Tech Stocks was not compensated by TempraMed Technologies Ltd. for this coverage, and the author holds no position in the securities mentioned. The reported sales figures are preliminary and unaudited, have not been independently verified and may change materially following the company’s closing procedures. The sales update did not disclose gross margin, operating income, cash flow or profitability, and recent monthly sales may not be sustained. TempraMed is an early-stage small-cap company facing commercialization, financing, manufacturing, distribution and regulatory risks. Information is current as of September 18, 2026. This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Read the full disclaimer.
